English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Streptococcus (S.) suis  is a major porcine pathogen causing high morbidity worldwide. This includes well-managed herds with high hygiene standards. In Europe, no licensed vaccine is available. As practitioners are obliged to reduce the use of antibiotics, autogenous  S. suis  vaccines have become very popular in Europe.    Main body  Autogenous vaccines (AV) are generally neither tested for safety, immunogenicity nor protective efficacy, which leads to substantial uncertainties regarding control of disease and return on investment. Here,  S. suis  publications are reviewed that include important data on epidemiology, pathologies and bacterin vaccination relevant for the use of AV in the field. Differences between herds such as the porcine reproductive and respiratory syndrome virus infection status and the impact of specific  S. suis  pathotypes are probably highly relevant for the outcome of immunoprophylaxis using autogenous  S. suis  bacterins. Thus, a profound diagnosis of the herd status is crucial for management of expectations and successful implementation of AV as a tool to control  S. suis  disease. Induction of opsonizing antibodies is an in vitro correlate of protective immunity elicited by  S. suis  bacterins. However, opsonophagocytosis assays are difficult to include in the portfolio of diagnostic services.    Conclusion  Autogenous  S. suis  bacterins are associated with limitations and risks of failure, which can partly be managed through improvement of diagnostics.

A critical review speculating on the protective efficacies of autogenous Streptococcus suis bacterins as used in Europe